SCHEMBL16193155

SCHEMBL16193155

Cc1nc2ccc(-c3ccccc3C(F)(F)F)nn2c1C(=O)Nc1cnncn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATR Q13535 1/20 0.38
▸ CYP1A2 P05177 4/20 0.38
▸ CYP3A4 P08684 3/20 0.38
▸ TSHR P16473 3/20 0.38
▸ CYP2C19 P33261 2/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ TGFBR1 P36897 1/20 0.37
▸ CHRM4 P08173 1/20 0.36
▸ NR3C1 P04150 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ NTRK1 P04629 3/20 0.35
▸ KMO O15229 2/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ HDAC1 Q13547 1/20 0.35
▸ SCN9A Q15858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14897129 0.88 CSNK1D (0.42) ATRTSHRTGFBR1CHRM4NR3C1
SCHEMBL14897428 0.87 CHRNB2 (0.43) ATRCYP1A2CYP3A4TSHRCYP2C19
SCHEMBL14896789 0.86 GRM5 (0.40) ATRALOX15NTRK1KMONPC1
SCHEMBL14897132 0.85 GRM5 (0.40) ATRCYP1A2CYP2C9TGFBR1NPC1
SCHEMBL14881923 0.85 RAB9A (0.43) TSHRNR3C1KDM4EALOX15TDP1
SCHEMBL14881482 0.84 NPC1 (0.37) ATRTGFBR1CHRM4NTRK1KMO
SCHEMBL14896619 0.84 MPL (0.43) CYP1A2CYP3A4TSHRCYP2C19CYP2C9
SCHEMBL14897468 0.84 NPC1 (0.36) ATRTGFBR1CHRM4NTRK1KMO
SCHEMBL14897467 0.82 SMN1; SMN2 (0.47) CYP1A2CYP3A4TSHRCYP2C19CYP2C9
SCHEMBL16265216 0.82 CYP1A2 (0.38) CYP1A2CYP3A4TSHRCYP2C19CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180186801-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2018-07-05 — — US disclosed
US-20180186801-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2018-07-05 — — US disclosed
US-9957271-B2 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2018-05-01 — — US disclosed
US-9957271-B2 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2018-05-01 — — US disclosed
EP-2768509-B1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2017-03-22 — — EP disclosed
US-20140349993-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2014-11-27 — — US disclosed
US-20140349993-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2014-11-27 — — US disclosed
WO-2013059587-A9 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2014-10-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140349993-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 ATR 1049/4885CYP1A2 1236/4885CYP3A4 1373/4885
US-20180186801-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 ATR 1049/4885CYP1A2 1236/4885CYP3A4 1373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback